Experimental blood pressure pill gets first safety check in humans
NCT ID NCT07174830
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing an experimental drug called allisartan isoproxil in 54 healthy Chinese adults. Participants will receive a single dose of either the drug or a placebo to see how the body processes it and whether it causes any side effects. The goal is to gather safety and dosing information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Allisartan isoproxil (an experimental blood pressure medication)
What this could lead to
If successful, this study will provide key safety and dosing data to support future trials of allisartan isoproxil for high blood pressure.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only tests single doses, so it cannot show whether the drug works for any condition. Side effects may still emerge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen People's Hospital
RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact